Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| May 08, 2015 | SVP, Chief Patient Advocate | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | VP, Regulatory Affairs | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | VP, Regulatory Affairs | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | VP, Legal & IP | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | VP, Legal & IP | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | VP Finance and Controller | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | VP Finance and Controller | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | SVP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | SVP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | VP Clinical Ops & Data Mgmt | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.